Lexeo Therapeutics, Inc. (LXEO)

NASDAQ: LXEO · Real-Time Price · USD

6.12

+0.10 (1.66%)

At close: Nov 20, 2024, 4:00 PM

6.42

+0.30 (4.90%)

After-hours: Nov 20, 2024, 6:40 PM EST

Lexeo Therapeutics Employees

Lexeo Therapeutics had 58 employees as of December 31, 2023. The number of employees increased by 34 or 141.67% compared to the previous year.

Employees

58

Change

34

Growth

141.67%

Revenue / Employee

n/a

Profits / Employee

-$1,493,034

Market Cap

202.36M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	58	34	141.67%
Dec 31, 2021	24	-	-

Related Stocks

Company Name	Employees
InfuSystem Holdings	516
Amarin Corporation	275
ADC Therapeutics	274
Enanta Pharmaceuticals	145
Profound Medical	131
XBiotech	82
Acrivon Therapeutics	61
Orchestra BioMed Holdings	56

Employee Rankings

LXEO News

8 days ago - Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
22 days ago - Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
4 weeks ago - Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference - GlobeNewsWire
2 months ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
3 months ago - Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
4 months ago - Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further - Seeking Alpha
4 months ago - Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet - Benzinga
4 months ago - Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy - GlobeNewsWire